药明康德发布年度业绩母公司持有者应占溢利93.53亿元每股基本盈利3.24元

Core Insights - WuXi AppTec reported a net profit attributable to shareholders of 9.353 billion RMB for the fiscal year ending December 31, 2024, with basic earnings per share of 3.24 RMB [1] - The company generated total revenue of 39.241 billion RMB, with a gross profit of 16.016 billion RMB [1] Revenue Breakdown - Revenue from the top 20 global pharmaceutical companies reached 16.64 billion RMB, with a year-on-year growth of 24.1% after excluding COVID-19 commercialization projects [1] - Revenue from U.S. clients amounted to 25.02 billion RMB, with a year-on-year growth of 7.7% after excluding COVID-19 commercialization projects [2] - Revenue from European clients was 5.23 billion RMB, reflecting a year-on-year increase of 14.4% [2] - Revenue from Chinese clients was 7.07 billion RMB, showing a year-on-year decline of 3.5% [2] - Revenue from other regions totaled 1.9 billion RMB [2] Client Activity - As of the end of 2024, the company had approximately 6,000 active clients, with about 5,500 in ongoing operations and 1,000 new clients added during the year [1] Future Outlook - The company anticipates a return to double-digit growth in its ongoing operations for 2025, projecting a revenue increase of 10% to 15%, with overall revenue expected to reach between 41.5 billion and 43 billion RMB [2] - The company will continue to focus on its CRDMO core business while gradually increasing production capacity [2]